Patents by Inventor Asi Haviv
Asi Haviv has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170258780Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.Type: ApplicationFiled: May 30, 2017Publication date: September 14, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Asi Haviv, Nora Tarcic
-
Publication number: 20170136003Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: January 19, 2017Publication date: May 18, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20170020857Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: October 6, 2016Publication date: January 26, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20160296512Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: June 20, 2016Publication date: October 13, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20160213663Abstract: This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis.Type: ApplicationFiled: April 4, 2016Publication date: July 28, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Asi Haviv, Nora Tarcic
-
Publication number: 20160193285Abstract: This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a selective estrogen receptor modulator (SERM) and/or a 2nd somatostatin receptor ligand (SRL).Type: ApplicationFiled: December 10, 2015Publication date: July 7, 2016Applicant: CHIASMA INC.Inventor: Asi Haviv
-
Publication number: 20150359788Abstract: This application provides for a method of treating a human patient afflicted with anti-TNF? refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.Type: ApplicationFiled: August 25, 2015Publication date: December 17, 2015Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Patent number: 9161935Abstract: This application provides for a method of treating a human patient afflicted with anti-TNF? refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.Type: GrantFiled: February 1, 2013Date of Patent: October 20, 2015Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20150086549Abstract: This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis.Type: ApplicationFiled: December 1, 2014Publication date: March 26, 2015Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Asi Haviv, Nora Tarcic
-
Publication number: 20150038508Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Asi Haviv, Nora Tarcic
-
Patent number: 8889661Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.Type: GrantFiled: March 2, 2011Date of Patent: November 18, 2014Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Asi Haviv, Nora Tarcic
-
Publication number: 20140200243Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: March 18, 2014Publication date: July 17, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20140057883Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: October 29, 2013Publication date: February 27, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Patent number: 8598203Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: GrantFiled: July 29, 2010Date of Patent: December 3, 2013Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20130203807Abstract: This application provides for a method of treating a human patient afflicted with anti-TNF? refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.Type: ApplicationFiled: February 1, 2013Publication date: August 8, 2013Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20130184310Abstract: This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis.Type: ApplicationFiled: March 5, 2013Publication date: July 18, 2013Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Asi Haviv, Nora Tarcic
-
Publication number: 20110218179Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.Type: ApplicationFiled: March 2, 2011Publication date: September 8, 2011Inventors: Asi Haviv, Nora Tarcic
-
Publication number: 20110217295Abstract: This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis.Type: ApplicationFiled: March 2, 2011Publication date: September 8, 2011Inventors: Asi Haviv, Nora Tarcic
-
Publication number: 20110027219Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: July 29, 2010Publication date: February 3, 2011Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye